PDF下载 ( 106 KB)
HCV Genotype, Serum HCV RNA Load, Liver Lesion and Efficacy of α-Interferon on Patients with Chronic Hepatitis C
-
摘要: 观察丙型肝炎基因型、病毒量及肝损程度对α干扰素治疗慢性丙型肝炎应答率的影响。对 41例慢性丙型肝炎用α干扰素 3MIU每天肌注一次 ,二周后改为隔日肌注一次 ,共 2 1周。治疗前用INNO -LIPA法作丙肝基因分型 ,并在治疗前、后每 2月及停药 6月时用PCR法检测HCVRNA含量和定性、每月检测肝功能。按国际标准判断干扰素的治疗末应答 （ETR）和持续应答 （SR）。结果显示 1b型HCVRNA的治疗末应答率占 82 8% （2 4/2 9） ;持续应答率占 78 9% （15 / 19）。ALT的应答率分别是 78 3 % （18/ 2 3）和 76 5 % （13/ 17）。HCVRNA含量显示≤ 5× 10 5copies/ml的持续应答率高于 >5× 10 5copies/ml,二组P <0 0 1。治疗前ALT活力高低与干扰素治疗后ALT的应答率影响不大。预测干扰素疗效的关键是治疗前HCVRNA在血清中的水平。Abstract: To observe the relationship between the genotype of HCV, Serum HCV RNA Load, ALT and efficacy of α-interferon on patients with chronic hepatitis C.3MIU of α-interferon was injected intramuscularly every day for 2 weeks at the beginning, then every otherday for 21 weeks in 41 patients with chronic hepatitis C.All patients were tested HCV genotype by INNO-LIPA before therapy.The quantitated and qualitited HCV RNA were measured by PCR before and after therapy every 2 months and 6 months.after treatment.Serum level of ALT and white blood cell were monitored every month after therapy.The rusults showned that 82.8% (24/29) HCV genotype 1b was the end of treatment response (ETR) , 78.9% (15/19) was the sustained response (SR) for HCV RNA.ALT of response was 78.3% (18/23) and 76.5% (13/17) , respectively, in HCV genotype 1b.The rate of sustained response of HC VRNA was higher in lower titier group (≤5×10 5copies/ml) than in high titer group[ (>5×10 5 copies/ml) , P<0.01].The response of ALT not ralated to the ALT level before therapy. (P>0.05) .The study show that serum HCV RNA load before therapy is important to predict the efficacy of α-interferon
-
[1]张顺财 , 刘厚钰 , 等 丙型肝炎病毒亚型与肝细胞癌关系的研究。临床肝胆病杂志 , 1996 , 12 (3) ∶135 [][2 ]EstebanR ManagingPatientsoninterferontherapy[J] Dig Dis Sci[J] , 1996 , 41 (12Suppl) ∶12 1 [3]KasaharaA , HayashiN , HiramatsuN , etal, AbillityofProlongedInterfironTreatmenttoSuppressRelapseafterCessationofTherapyinPatientswithChronicHapatitisC∶AMulticenterRandomizedControlledTrial[J] Hepatology , 1995 , 2 1∶2 91 [4]MizkamiM , OritoE , GiboY , etal GenotypeserumlevelofhepatitisCVirusRNAandliverhistologyaspredictorsofresponsetointerferon α 2atherapyinJapanesepatientswithchronichapatitisC[J] Liver, 1995 , 16∶2 3 [][5 ]YamadaG , TakataniM , KishiF , etal EfficacyofInterferonAlfaTherapyinChronicHapatitisCVirusRNALevel[J] Hepatology , 1995 , 2 2∶135 1 [][6 ]OritoE , MizokamiM , SuzukiK , etal LossofserumHCVRNAatweek 4ofInterferon αTherapyisAssociatedwithmorefavorablelong termResponseinPatientswithChronicHapatitisC[J] JMedVirol, 1995 , 46∶10 9 [7] 姚光弼 , 丙型肝炎的进展和共识 [J] .肝脏 , 1998, 3∶16 8 -
下载:
